NUCC-0196361 MedChemExpress (MCE)

Product Name	MYCi361
Synonyms	MYCi361 NUCC-0196361 MYCi361 (NUCC-0196361) 6-((4-Chlorobenzyl)oxy)-3-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-3',5'-bis(trifluoromethyl)-[1,1'-biphenyl]-2-ol [1,1'-Biphenyl]-2-ol, 6-[(4-chlorophenyl)methoxy]-3-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-3',5'-bis(trifluoromethyl)-
CAS	2289690-31-7
EINECS
Chemical Formula	C26H16ClF9N2O2
Molecular Weight	594.86
inchi
Package	10 mM * 1 mL;1 mg;5 mg;10 mg
Price	Email to quote
Descriptions	MYCi361 MYCi361 MedChemExpress (MCE) HY-129600 2289690-31-7 NUCC-0196361 99.85% Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Room temperature in continental US Descriptions MYCi361 MYCi361 MedChemExpress (MCE) HY-129600 2289690-31-7 NUCC-0196361 99.85% Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Room temperature in continental US may vary elsewhere. MYCi361 (NUCC-0196361) is a MYC inhibitor with the Kd of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy. MYCi361 inhibits the viability of MYC-dependent cancer cells including prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2) with low-micromolar IC50 values[1]. MYCi361 inhibits MYC-dependent tumor growth in vivo. MYCi361 treatment (100 mg/kg/day for 2 days then 70 mg/kg/day for 9 days) induces tumor regression in FVB or NSG male mice[1]. MYCi361 has moderate terminal elimination half-life of 44 and 20 h for intraperitoneal (i.p.) or oral (p.o.) dosing in mice, respectively[1]. MYCi361 suppresses tumor growth in mice, increases tumor immune cell infiltration, upregulates PD-L1 on tumors, and sensitizes tumors to anti-PD1 immunotherapy. However, MYCi361 demonstrates a narrow therapeutic index. An improved analog, MYCi975 shows better tolerability[1]. \| \| \| \| \| \| \| \| \| \| [1]. Han H, et al. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell. 2019 Nov 11 36(5):483-497.e15. [Content Brief]
Supplier Website	https://www.medchemexpress.com/myci361.html
Last Update	2025-05-21 16:50:25

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-05-21 16:50:25

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-05-21 16:50:25

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-05-21 16:50:25

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-05-21 16:50:25

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-05-21 16:50:25

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-05-21 16:50:25

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-05-21 16:50:25

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-05-21 16:50:25


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact